Et2Zn-mediated stoichiometric C(sp)-H silylation of 1-alkynes and chlorosilanes

A first example of an Et₂Zn mediated silylation of 1-aklynes is reported. A series of functional groups are tolerated in this reaction. Mechanistic studies support Zn alkynilides as intermediates in the reaction. This reaction protocol provides a practical method for the preparation of alkynylsilanes and expands the application of organometallic zinc in organic synthesis.     

Zur Theorie der analytischen Funktionen mehrerer komplexer Veränderlichen

Ohne Zusammenfassung     

Algebraic algorithms for the analysis of mechanical trusses

Infinite periodic lattices can be used as models for analyzing and understanding various properties of mechanical truss constructions with periodic structures. For infinite lattices, the problems of connectivity and stability are nontrivial from the mathematical point of view and have not been addressed adequately in the literature. In this paper, we will present a set of algebraic algorithms, which are based on ideal theory, to solve such problems.

For the understanding of the notion ``complicated three-dimensional lattices', it is essential to have this paper with colored figures.

     

Connectedness of the Isospectral Manifold for One-Dimensional Half-Line Schrödinger Operators

Journal of Statistical Physics - Let V 0be a real-valued function on [0,∞) and V∈L 1([0,R]) for all R&;gt;0 so that H(V 0)=? $\frac{{d^2 }}{{dx^2 }}$ +V 0in L 2([0,∞))...     

Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy

Bionized nanoferrite (BNF) particles with high specific power absorption rates were synthesized in the size range of 20–100 nm by high-pressure homogenization for targeted cancer therapy with alternating magnetic fields. Several strategies were used to conjugate antibodies to the BNF particles. These strategies were compared using an immunoassay to find optimal conditions to reach a high immunoreactivity of the final antibody–particle conjugate.